XERS - Xeris Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.30
-0.52 (-5.90%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.82
Open8.78
Bid8.00 x 900
Ask8.30 x 1000
Day's Range8.11 - 9.13
52 Week Range6.85 - 20.79
Volume277,769
Avg. Volume133,873
Market Cap224M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on November 27, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 8,000 shares of its common stock to 4 new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • GlobeNewswire

    Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Xeris’ Chairman and CEO, provided an update of its portfolio programs during a fireside chat at the Jefferies London Healthcare Conference. A replay of Mr. Edick’s remarks is available on the Company’s website.

  • GlobeNewswire

    Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights

    Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription MAA for ready-to-use glucagon on track for submission to EMA by year-end Data from three.

  • GlobeNewswire

    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 30, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 81,000 shares of its common stock to 61 new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • GlobeNewswire

    Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

    CHICAGO, Oct. 01, 2019 -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and.

  • GlobeNewswire

    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    CHICAGO, Aug. 30, 2019 -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize.

  • GlobeNewswire

    Xeris Pharmaceuticals to Present at Two September Healthcare Conferences

    CHICAGO, Aug. 29, 2019 -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and.

  • GlobeNewswire

    Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights

    CHICAGO, Aug. 06, 2019 -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and.

  • GlobeNewswire

    Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on July 31, 2019, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 1,500 shares of its common stock to 2 new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Business Wire

    Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that is has dosed the first subject in a Phase 2 trial with its developmental ready-to-use glucagon in patients who experience hypoglycemic episodes following bariatric surgery. Post-bariatric hypoglycemia (PBH) is a complication of bariatric surgery thought to be related to excessive insulin secretion in response to a meal.

  • Business Wire

    Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from a global Phase 3 trial of its ready-to-use (RTU) room-temperature stable liquid glucagon conducted in Europe and North America. The Phase 3, multi-center, randomized controlled, non-inferiority study was conducted among 132 adults with type 1 diabetes to evaluate the Xeris RTU glucagon auto-injector as a treatment for severe hypoglycemic events as compared with Novo Nordisk’s GlucaGen® HypoKit®. The results demonstrated comparable efficacy between the two groups for achieving a plasma glucose of 70 mg/dl or ≥20 mg/dl increase in plasma glucose concentration within 30 minutes of glucagon administration.

  • GlobeNewswire

    Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline

    Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ and Gvoke PFS™ Dosed first patient in a Phase 2 study evaluating ready-to-use (RTU) glucagon in.

  • GlobeNewswire

    Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam

    The Phase 1, open-label, three-treatment, three-way crossover, randomized controlled study was conducted among 24 healthy volunteers to assess the bioavailability and pharmacokinetics (PK) of Xeris’ novel formulation of diazepam after intramuscular (IM) and subcutaneous (SC) administration compared to an administration of commercial diazepam rectal gel (Diastat®). Secondary objectives were to assess the safety and tolerability of Xeris’ diazepam after SC and IM administration.

  • Business Wire

    Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it is presenting data on its developmental ready-to-use (RTU) room-temperature stable liquid glucagon at two medical conferences. “Our R&D efforts continue to provide support for the value of our novel formulation technology platform for not only patients and providers, but for payers and healthcare systems as well,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals.

  • Business Wire

    Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia

    Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia (EIH). “Many individuals with diabetes treated with insulin experience EIH and the complexity of managing it is a major barrier to the adoption of regular physical activity.

  • GlobeNewswire

    Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress

    Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of.